SCHEMBL15224249

SCHEMBL15224249

CC1CC(C)CN(C(=O)CCC(N)=O)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
RECQL P46063 1/20 0.42
POLB P06746 2/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
CHRNB3 Q05901 1/20 0.42
CHRNA6 Q15825 1/20 0.42
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.39
GAA P10253 1/20 0.39
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15224147 0.82 ALDH1A1 (0.44) ALDH1A1HPGDRECQLMEN1KMT2A
SCHEMBL15224148 0.82 POLB (0.46) ALDH1A1HPGDRECQLPOLBCHRNB2
SCHEMBL14543538 0.80 CHRNB2 (0.63) ALDH1A1HPGDRECQLPOLBCHRNB2
SCHEMBL15224250 0.79 NPC1 (0.47) ALDH1A1HPGDRECQLPOLBCHRNB2
SCHEMBL15224183 0.79 KMT2A (0.67) ALDH1A1HPGDRECQLPOLBMEN1
SCHEMBL17040286 0.78 CHRNB2 (0.36) ALDH1A1POLBCHRNB2CHRNA3CHRNA4
SCHEMBL7507184 0.78 ALDH1A1 (0.46) ALDH1A1HPGDRECQLCHRNB2CHRNA3
SCHEMBL15224179 0.77 NPC1 (0.69) ALDH1A1HPGDPOLBMEN1KMT2A
SCHEMBL12846054 0.75 CHRNB2 (0.61) ALDH1A1HPGDRECQLPOLBCHRNB2
SCHEMBL5386339 0.74 GAA (0.46) ALDH1A1HPGDCHRNB2CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885HPGD 50/4885RECQL 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.